FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., a veterinary cancer therapeutics company, today announced
that the U.S. Food and Drug Administration’s Center for Veterinary
Medicine (CVM) has granted a conditional approval of Tanovea™-CA1
(rabacfosadine for injection) for the treatment of
lymphoma in dogs. Tanovea-CA1 is anticipated to be available to
veterinarians in the spring of 2017.
“This is a significant milestone for VetDC, and we are excited to
announce the first ever FDA-approved drug for canine lymphoma,” stated
Steven Roy, VetDC’s President and CEO. “We look forward to introducing
Tanovea-CA1 to the veterinary cancer community in the months to come.”
“The conditional approval of Tanovea-CA1 represents a first on multiple
levels for veterinary oncology, and we eagerly anticipate adding this
very active and promising new drug to our lymphoma fighting arsenal,”
noted Dr. Philip J. Bergman, a board-certified veterinary oncologist at
VCA-Katonah Bedford Veterinary Center in Bedford Hills, NY.
Tanovea-CA1 (rabacfosadine for injection) is a novel small molecule drug
designed to preferentially target and attack rapidly dividing cancer
cells implicated in lymphoma. Tanovea-CA1 has demonstrated anti-tumor
activity in both naïve and relapsed canine lymphoma cases, with a
generally well-tolerated safety profile. Tanovea-CA1 is administered
intravenously every three weeks for up to five doses.
About Canine Lymphoma
Lymphoma is one of the most common types of cancer in dogs. Lymphoma
originates from white blood cells called lymphocytes. These cells are a
normal part of the immune system and protect the body from infection,
but in lymphoma, they grow abnormally. Although lymphoma can affect
virtually any organ in the body, it most commonly starts in organs that
function as part of the immune system, such as the lymph nodes, spleen,
and bone marrow. The signs of lymphoma in dogs vary depending on which
organs are affected. The cause of canine lymphoma is unknown.
About VetDC, Inc.
VetDC (www.vetdc.com), a Colorado
State University startup, is changing the way new cancer medicines are
developed for companion animals, leveraging novel advancements from
human biotechnology that have demonstrated success in animal studies. In
addition to Tanovea-CA1 for canine lymphoma, VetDC is developing
VDC-597, a novel, dual-acting PI3K/mTOR inhibitor for multiple
Steven J. Roy, President & CEO